Literature DB >> 2808688

Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: possible role in autoimmune pathogenesis.

S Cohen-Kaminsky1, P Levasseur, J P Binet, S Berrih-Aknin.   

Abstract

We evaluated the activation state of thymic lymphocytes in patients with myasthenia gravis (MG) by cytofluorographic analysis of CD25 expression and by testing their sensitivity to recombinant interleukin-2 (rIL-2) in the absence of any known previous stimulation. We detected no phenotypic signs of activation in fresh MG thymic lymphocyte suspensions, while functional signs of activation were reflected in a significantly higher sensitivity to rIL-2 in MG patients than in controls. The responses to rIL-2 were time- and dose-dependent, were inhibited by a blocking anti-IL-2 receptor antibody, and were associated with an increase in CD25+ T cells in both patients and controls. The T cells with functional signs of previous activation may represent autoreactive cells involved in the autoimmune process and confirm thymus gland hyperactivity in MG. These cells could result from primary autosensitization against the thymic acetylcholine receptor (AChR)-like molecule or from altered migration of peripheral activated cells into an abnormal thymic environment. Our results also provide a clue for understanding the effect of thymectomy in myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808688     DOI: 10.1016/0165-5728(89)90101-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

2.  Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics.

Authors:  A Wakkach; S Poea; E Chastre; C Gespach; F Lecerf; S De La Porte; S Tzartos; A Coulombe; S Berrih-Aknin
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

3.  Myasthenia gravis induces the activation and maturation of lymphocytes in thymoma.

Authors:  K Takahashi; Y Monden; S Saito; Y Kamamura; T Uyama
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

4.  Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.

Authors:  Florence Jambou; Wei Zhang; Monique Menestrier; Isabelle Klingel-Schmitt; Olivier Michel; Sophie Caillat-Zucman; Abderrahim Aissaoui; Ludovic Landemarre; Sonia Berrih-Aknin; Sylvia Cohen-Kaminsky
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

5.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

Authors:  Anna Balandina; Sandrine Lécart; Philippe Dartevelle; Abdelhadi Saoudi; Sonia Berrih-Aknin
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

6.  In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.

Authors:  C Aime; S Cohen-Kaminsky; S Berrih-Aknin
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

Review 7.  Regulatory T cells in multiple sclerosis and myasthenia gravis.

Authors:  K M Danikowski; S Jayaraman; B S Prabhakar
Journal:  J Neuroinflammation       Date:  2017-06-09       Impact factor: 8.322

8.  Comparative Analysis of Thymic and Blood Treg in Myasthenia Gravis: Thymic Epithelial Cells Contribute to Thymic Immunoregulatory Defects.

Authors:  Frédérique Truffault; Dani Nazzal; Julien Verdier; Angeline Gradolatto; Elie Fadel; Régine Roussin; Bruno Eymard; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

Review 9.  Immunoregulatory Cells in Myasthenia Gravis.

Authors:  Ying Wu; Jie Luo; Oliver A Garden
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.